Meropenem Aurobindo

Meropenem, the active ingredient in Meropenem Aurobindo, is a carbapenem antibiotic presented as an intravenous formulation for hospital use. It treats a range of serious bacterial infections in adult and paediatric patients when other antibiotics are ineffective.

GNH USA supplies Meropenem Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem used for severe bacterial infections that require intravenous therapy. - Complicated intra‑abdominal infections: provides rapid bactericidal activity to resolve deep abdominal sepsis. - Complicated urinary tract infections: eradicates resistant uropathogens causing pyelonephritis. - Nosocomial pneumonia: treats hospital‑acquired lung infections, including ventilator‑associated pneumonia. - Meningitis: penetrates the cerebrospinal fluid to eliminate causative bacteria. - Severe sepsis and septic shock: offers critical coverage against multidrug‑resistant organisms.

Adverse reactions may occur with any intravenous antibiotic. Monitoring and prompt reporting are essential.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhoea: may be watery and self‑limiting. - Rash: erythematous skin eruption. - Infusion site reactions: redness or pain at the injection site.

Serious or Rare Side Effects: - Seizures: especially in patients with pre‑existing CNS disorders. - Clostridioides difficile colitis: severe diarrhoea due to gut flora disruption. - Anaphylaxis: acute, potentially life‑threatening hypersensitivity. - Severe neutropenia: marked reduction in white blood cells. - Renal toxicity: impaired kidney function in susceptible individuals. - Stevens‑Johnson syndrome: rare mucocutaneous blistering disorder.

Careful patient assessment and monitoring are required before and during therapy. - Renal function monitoring: adjust dose in renal impairment. - Hypersensitivity assessment: discontinue if allergic reaction occurs. - CNS disorder caution: avoid in patients with seizure history. - Concomitant valproic acid: increased seizure risk, consider alternatives. - Drug‑induced neutropenia: monitor complete blood count regularly. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Potential drug‑drug interactions should be evaluated to minimise adverse outcomes.

Major Interactions (Avoid): - Valproic acid: heightened risk of seizures. - CNS depressants: additive sedative effects. - Loop diuretics: may exacerbate nephrotoxicity.

Moderate Interactions (Monitor Closely): - Aminoglycosides: monitor renal function for additive toxicity. - Vancomycin: watch for combined nephrotoxic potential. - Warfarin: observe INR for possible anticoagulation changes.